SCHEMBL18223779

SCHEMBL18223779

COc1ccc(CNC(=O)OC(C)(C)C)cc1-c1ccc(C(F)(F)F)nn1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.41
▸ GRM2 Q14416 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ RCE1 Q9Y256 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ PTGDR2 Q9Y5Y4 1/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ PTGES O14684 1/20 0.38
▸ DYRK1A Q13627 1/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ PDE11A Q9HCR9 1/20 0.38
▸ PPARA Q07869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16894164 0.80 BRD4 (0.45) TRPV1GRM2L3MBTL1DYRK1A
SCHEMBL6681923 0.74 ALDH1A1 (0.52) TRPV1ALDH1A1GAAHTTLMNA
SCHEMBL7370094 0.74 TRPV1 (0.61) TRPV1ALDH1A1KDM4EGAA
SCHEMBL24838807 0.73 ALDH1A1 (0.51) GRM2ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL10165058 0.73 ALDH1A1 (0.51) GRM2ALDH1A1
SCHEMBL6185932 0.73 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2KDM4EL3MBTL1
SCHEMBL10263975 0.73 L3MBTL1 (0.50) TRPV1ALDH1A1KDM4EGAANPSR1
SCHEMBL32665628 0.72 ALDH1A1 (0.48) TRPV1GRM2ALDH1A1L3MBTL1
SCHEMBL30696410 0.72 KLKB1 (0.40) TRPV1ALDH1A1SMN1; SMN2LMNA
SCHEMBL27174466 0.72 KLKB1 (0.40) TRPV1ALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same EA PHARMA CO., LTD. (JP) 2020-04-21 — — US disclosed
EP-3101015-B1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO LTD (JP) 2019-09-18 — — EP disclosed
EP-3101015-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA Pharma Co., Ltd. (JP) 2016-12-07 — — EP disclosed
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO., LTD. (JP) 2016-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME TRPA1, TRPV1, TRPV2 TRPV1 2/4885GRM2 568/4885ALDH1A1 546/4885
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same TRPA1, TRPV1, TRPV2 TRPV1 2/4885GRM2 568/4885ALDH1A1 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback